Tonix Pharmaceuticals (TNXP) reported favorable results for the tests on its lead drug candidate TNX 102 SL. The pharma company had conducted fed-fasting and dose proportionality tests of the drug candidate in healthy volunteers. The data will be used to support a New Drug Application for treating post-traumatic stress disorder and fibromyalgia.
The results showed that there was no significant effect of a fatty meal on the rate or extent of absorption of TNX-102 SL 5.6 mg. The drug was administered as 2 x 2.8 mg sublingual tablets. This finding is in line with transmucosal